Sanofi (LON:0A2V)
London flag London · Delayed Price · Currency is GBP · Price in USD
48.27
+0.26 (0.54%)
At close: Dec 19, 2025

Revenue

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212011 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2011 - 2020
Dupixent Revenue
14.93B13.07B
Log In
Log In
Log In
Upgrade
Total Neurology & Immunology Revenue
--
Log In
Log In
Log In
Upgrade
Total Rare Diseases Revenue
--
Log In
Log In
Log In
Upgrade
Total Oncology Revenue
--
Log In
Log In
Log In
Upgrade
Total Rare Blood Disorders Revenue
--
Log In
Log In
Log In
Upgrade
Pharma Revenue
34.81B32.78B
Log In
Log In
Log In
Upgrade
Total Vaccine Revenue
8.07B8.30B
Log In
Log In
Log In
Upgrade
BioPharma Revenue
42.89B41.08B
Log In
Log In
Log In
Upgrade
Specialty Care Revenue
--
Log In
Log In
Log In
Upgrade
Total Core Assets Revenue
--
Log In
Log In
Log In
Upgrade
Total Non-Core Assets Revenue
--
Log In
Log In
Log In
Upgrade
Industrial Revenue
--
Log In
Log In
Log In
Upgrade
Total Pharmaceutical Revenue
--
Log In
Log In
Log In
Upgrade
Opella Consumer Healthcare Revenue
--
Log In
Log In
Log In
Upgrade
Revenue (Other)
-11.88B-9.87B
Log In
Log In
Log In
Upgrade
Revenue (Total)
45.93B44.29B
Log In
Log In
Log In
Upgrade

Revenue by Geography

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212011 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2011 - 2020
United States Revenue
21.52B19.99B
Log In
Log In
Log In
Upgrade
Europe Revenue
9.17B9.03B
Log In
Log In
Log In
Upgrade
Rest of World Revenue
12.20B12.07B
Log In
Log In
Log In
Upgrade
Revenue (Other)
3.04B3.21B
Log In
Log In
Log In
Upgrade
Revenue (Total)
45.93B44.29B
Log In
Log In
Log In
Upgrade

EBIT

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212011 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2011 - 2020
Biopharma Operating Income
11.82B11.29B
Log In
Log In
Log In
Upgrade
Opella Consumer Healthcare (Post-2022 Reporting) Operating Income
--
Log In
Log In
Log In
Upgrade
Other (Post-2022 Reporting) Operating Income
63.00M58.00M
Log In
Log In
Log In
Upgrade
Pharmaceutical Operating Income
--
Log In
Log In
Log In
Upgrade
Vaccine Operating Income
--
Log In
Log In
Log In
Upgrade
Consumer Healthcare Operating Income
--
Log In
Log In
Log In
Upgrade
Other Operating Income
--
Log In
Log In
Log In
Upgrade
Operating Income (Other)
-3.56B-4.09B
Log In
Log In
Log In
Upgrade
Operating Income (Total)
8.33B7.25B
Log In
Log In
Log In
Upgrade
Updated Sep 30, 2025. Data Source: Fiscal.ai.